RACEMISTAT

Produit de santé naturel homologué au Canada

Titulaire: Pascal International Corporation
NPN ou DIN-HM: 00407658
Statut: Licence non active
Date de licence: 11 octobre 2007
Date de révision: Non renseignée
Forme: Liquide
Voie d'administration: Dentaire
Type de demande: DIN de transition

L’analyse des doses orales ne s’applique pas sans voie exclusivement orale établie.

Composition

Composition médicinale non renseignée.

Ingrédients non médicinaux

Eau purifiée, Phosphate de sodium, monobasique, monohydraté, Sodium Bisulfite, Acide phosphorique, Hydroxyde d'ammonium, alcool benzylique, Sodium Thiosulphate, anhydrous, Chlorure de zinc, Chlorure de sodium, Sodium Dithionite

Doses recommandées au Canada

Population	Âge	Quantité par prise	Fréquence
Adultes	Non précisée	minimum : 1 Goutte(s) ; maximum : 3 Goutte(s)	Non précisée
Enfants	Non précisée	minimum : 1 Goutte(s) ; maximum : 3 Goutte(s)	Non précisée

Usages autorisés au Canada

Use in professional dental practice for tissue retraction and local hemostasis. This is an effective agent for shrinking gingival tissue and eliminating capillary oozing by temporary vasocinstriction.

Un usage autorisé au Canada n'est pas une allégation de santé autorisée dans l'Union européenne. Consultez le registre des allégations de santé.

Mises en garde au Canada

Précautions et mises en garde
Use only enough solution to produce desired hemostatic effect. Solution should be left in contact with tissue for no longer than two minutes. Use should be limited to one quadrant of the mouth. Shelf life will be aided by avoiding introduction of contaminants into the bottle such as cotton pellets, cord and mental instruments. To use, transfer a few drops to separate container.
Contre-indications
Persons with cardiovascular disease, diabetes, hyperthyroidism or hypertension. Avoid use where bone is exposed, as in apicoectomy and gingivectomy, and in endodontic procedures where apical faramen is not fully formed.
Effets indésirables connus
Contains Sodium Bisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in normal asthmatic people.